Nature: How is a bone marrow-boosting tumor hereditary?

Bone marrow-boosting tumors (MPNs) are a series of blood cancers characterized by over-birth of mature myelin cells.
, although MPNs are produced from sophyte-driven mutations, past work has shown that the disease has a considerable genetic component.
of first-degree relatives in
MPNs patients had a 5-7 times increased risk of developing MPNs, with a greater family risk than breast cancer (relative risk (RR) s 3.5), prostate cancer (RR=2.46) and colorectal cancer (RR=2.25).
genetic studies have identified a limited set of places associated with MPN susceptibleness.
, however, many key aspects of the genetic MPN risk remain unmediative, including pathogenic genes, cell types and the potential biological mechanisms involved.
, researchers recently published a paper in the journal Nature, which identified 17 MPN risk points (P.lt;5.0×10-8), seven of which had not previously been reported, through a large-scale genome-wide association study (3,797 cases and 1,152,977 controls).
researchers found that MPN risk has a common genetic structure with several hematogenic traits from different bloodlines; that MPN risk variation is rich within HSCs-accessible chromatin; and that increased MPN risk is associated with longer telomere lengths in white blood cells and other cloned hematosis states -- a common reminder that MPN risk is associated with HSCs function and self-renewal.
researchers also used gene maps to identify HSC biological regulatory factors associated with MPN risk, and targeted mutation-to-functional determination showed that CHEK2 and GFI1B played a role in altering the function of HSCs to give disease risk.
, the results of this study reveal a previously under-valued mechanism for achieving hereditary MPN risk by regulating HSC functions.
.